Detecting genomic differences in pediatric patients with brain tumors under Temozolomide treatment
碩士 === 國立陽明大學 === 生命科學暨基因體科學研究所 === 95 === Many studies indicated the expression of O6-methylguanine DNA methyltransferase (MGMT) enzyme was related to the efficacy of temozolomide in patients with tumors. Due to the fact that the methylation of CpG island on MGMT promoter inhibits the expression of...
Main Authors: | Meng-Shu Chieh, 階孟書 |
---|---|
Other Authors: | Yann-Jang Chen |
Format: | Others |
Language: | en_US |
Published: |
2007
|
Online Access: | http://ndltd.ncl.edu.tw/handle/68618798651184788162 |
Similar Items
-
Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations
by: Margarita García, et al.
Published: (2009-10-01) -
Temozolomide: Anti-tumor effect on giant, invasive and resistant pediatric prolactinoma
by: Farida Chentli, et al.
Published: (2013-01-01) -
Temozolomide and oral etoposide in children with recurrent malignant brain tumors
by: Antonio Ruggiero, et al.
Published: (2020-06-01) -
β-elemene combined with temozolomide in treatment of brain glioma
by: Xiaomin Zhang, et al.
Published: (2021-12-01) -
Focused ultrasound enhanced chemotherapeutic agent (Temozolomide) delivery for brain tumor treatment: A preclinical investigation
by: Ju Yu Chen, et al.
Published: (2014)